WO2025172910 - FACTOR B INHIBITORS FOR TREATMENT OF ANCA-ASSOCIATED VASCULITIS
National phase entry is expected:
Publication Number
WO/2025/172910
Publication Date
21.08.2025
International Application No.
PCT/IB2025/051592
International Filing Date
14.02.2025
Title **
[English]
FACTOR B INHIBITORS FOR TREATMENT OF ANCA-ASSOCIATED VASCULITIS
[French]
INHIBITEURS DU FACTEUR B POUR LE TRAITEMENT DE LA VASCULARITE ASSOCIÉE AUX ANCA
Applicants **
NOVARTIS AG
Inventors
HANSER, Malika Amel
JUNGE, Guido
MEIER, Matthias
Priority Data
63/554,458
16.02.2024
US
63/728,854
06.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6958 | |
| EPO | Filing, Examination, Granting | 176824 | |
| Japan | Filing, Examination, Granting | 5168 | |
| South Korea | Filing, Examination, Granting | 11123 | |
| USA | Filing, Examination, Granting | 41440 |
Total:
241,513
Contact Us
Abstract[English]
Described herein are methods of treating ANCA-associated vasculitis (AAV) with the Factor B inhibitor iptacopan or a pharmaceutically acceptable salt thereof, e.g., iptacopan hydrochloride, or hydrate thereof.[French]
L'invention concerne des méthodes de traitement de la vascularite associée aux ANCA (AAV) avec l'iptacopan de l'inhibiteur du facteur B ou un sel pharmaceutiquement acceptable de celui-ci, par exemple, le chlorhydrate d'iptacopan, ou un hydrate de celui-ci.